Aspirin-Resistant Patients at Heart Risk
Posted on: Monday, 21 January 2008, 15:00 CST
Being resistant to aspirin makes patients four times more likely to suffer a heart attack, stroke or dying from a heart condition, Canadian researchers found.
The study involved patients who are prescribed aspirin long-term as a way of preventing clots from forming in the blood.
Researchers at Toronto General Hospital said patients labeled aspirin resistant have blood cells, or platelets, which aren't affected in the same way as those of patients who are responsive to the drug, or people labeled aspirin sensitive.
The researchers identified 20 studies, involving 2,930 patients with cardiovascular disease, all of whom had been prescribed aspirin as a way of preventing clots from forming in the blood -- 28 percent were classified as aspirin resistant.
The study, published in the British Medical Journal, concluded that there needs to be further studies on aspirin resistance to identify the most useful test to determine the condition.
The researchers also said aspirin resistance is a biological entity that should be considered when recommending aspirin as antiplatelet therapy.
Source: United Press International
Related Articles
- New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions
- 50th Annual Meeting of the American Society of Hematology Will Feature Breakthrough Research in Blood Diseases
- Half Of Patients With Extensively Drug-resistant TB Die
- Patient’s Manage High Blood Pressure Over the Internet
- BD Announces FDA 510(K) Clearance of Two-Hour Test to Identify Superbug in Patients With Positive Blood Cultures
- Market Research Suggests Internet Recruitment Is Reducing Clinical Trial Costs; 85 Percent of Patients Research Ailments Online
- Exforge(R) Receives Final US Approval As New and Powerful Treatment Option for Patients With High Blood Pressure
- MD Hospital Industry Defeats Bill Requiring Patient Screening for Antibiotic-Resistant Bacteria
- Tampa General Hospital Approved to Enroll Patients in Synthetic Blood International's Phase II Oxycyte Trial
- Lowering BP With Medication Provides Unexpected Benefits for Heart Disease Patients With 'Normal' Blood Pressure
 |
 |
User Comments (0)
RSS Feeds